[Therapeutic Options in Vitreomacular Traction With or Without a Macular Hole]. / Therapie der vitreomakulären Traktion mit und ohne Makulaforamen.
Klin Monbl Augenheilkd
; 233(5): 622-30, 2016 May.
Article
em De
| MEDLINE
| ID: mdl-27187883
ABSTRACT
Treatment is usually indicated for symptomatic vitreomacular traction (VMT) with or without a full thickness macular hole (FTMH) and without spontaneous resolution. Ultrastructural parameters are evaluated by SD-OCT, in order to classify the vitreoretinal interface and to estimate the success rate of treatment. The resolution rate after therapy with intravitreal Jetrea® (Ocriplasmin) is high (up to 70â%) in patients with symptomatic focal vitreomacular traction (≤ 1500 µm) with or without a macular hole (≤ 250 µm) and with no epiretinal membrane (ERM), but depends on the exact baseline analysis. All other patients with idiopathic traction retinopathy should be treated by minimal invasive pars plana vitrectomy (MIVI). Vitreoretinal surgery effectively removes traction and gives a high closure rate of a full thickness macular hole (FTMH, 90 to 100â%). It is now a very safe procedure with few side effects. Despite a low risk profile (cataract, retinal tear etc.) the indication for surgery needs to take the safety profile into account. Therefore vitrectomy is only indicated in symptomatic patients complaining of blurred vision, VA reduction and metamorphopsia. Vitrectomy is also indicated in patients whose treatment by pharmacologic vitreolysis has failed.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Perfurações Retinianas
/
Descolamento Retiniano
/
Aderências Teciduais
/
Descolamento do Vítreo
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
De
Ano de publicação:
2016
Tipo de documento:
Article